Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Top Midday Gainers

Top Midday Gainers

MT newswireMT newswire2026/10/05 17:58

01:58 PM EDT, 10/05/2026 (MT Newswires) -- WISeSat.Space (SAIQ) shares soared 260% amid heavy trading after the company, a subsidiary of WISeKey (WKEY), completed its business combination with Columbus Acquisition on Friday. More than 55.4 million shares of WISeSat.Space traded intraday compared with a daily average of about 138,000. Veea (VEEA) received unsecured loans totaling $1.65 million from NLabs, a principal stockholder and an affiliate of its chief executive officer, the company said in a regulatory filing Friday. Veea shares surged 50% as intraday trading volume climbed to over 45.2 million, versus a daily average of roughly 5.56 million. Vaxcyte (PCVX) said its experimental VAX-31 drug candidate met all pre-specified primary endpoints across age groups studied, compared with Prevnar 20 and/or Capvaxive, in a phase 3 trial of the invasive pneumococcal disease and pneumococcal pneumonia treatment. Shares jumped 30%, with intraday trading volume at 10.6 million versus a daily average of about 1.15 million. Price: 6.86, Change: +5.01, Percent Change: +270.81

01:58 PM EDT, 10/05/2026 (MT Newswires) -- WISeSat.Space (SAIQ) shares soared 260% amid heavy trading after the company, a subsidiary of WISeKey (WKEY), completed its business combination with Columbus Acquisition on Friday. More than 55.4 million shares of WISeSat.Space traded intraday compared with a daily average of about 138,000. Veea (VEEA) received unsecured loans totaling $1.65 million from NLabs, a principal stockholder and an affiliate of its chief executive officer, the company said in a regulatory filing Friday. Veea shares surged 50% as intraday trading volume climbed to over 45.2 million, versus a daily average of roughly 5.56 million. Vaxcyte (PCVX) said its experimental VAX-31 drug candidate met all pre-specified primary endpoints across age groups studied, compared with Prevnar 20 and/or Capvaxive, in a phase 3 trial of the invasive pneumococcal disease and pneumococcal pneumonia treatment. Shares jumped 30%, with intraday trading volume at 10.6 million versus a daily average of about 1.15 million. Price: 6.86, Change: +5.01, Percent Change: +270.81
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!